172 related articles for article (PubMed ID: 3963041)
1. Spontaneous hypercalcemia in patients undergoing dialysis. Etiologic and therapeutic considerations.
Piraino BM; Rault R; Greenberg A; Dominguez JH; Wallia R; Houck P; Segre GV; Chen T; Foti FM; Puschett JB
Am J Med; 1986 Apr; 80(4):607-15. PubMed ID: 3963041
[TBL] [Abstract][Full Text] [Related]
2. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
Piraino B; Chen T; Puschett JB
Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia.
Andress D; Felsenfeld AJ; Voigts A; Llach F
Kidney Int; 1983 Sep; 24(3):364-70. PubMed ID: 6645210
[TBL] [Abstract][Full Text] [Related]
4. Bone aluminum and histomorphometric features of renal osteodystrophy.
Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW
J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
[TBL] [Abstract][Full Text] [Related]
5. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
[TBL] [Abstract][Full Text] [Related]
6. Renal osteodystrophy--pathogenesis and treatment.
Cushner HM; Adams ND
Am J Med Sci; 1985 Dec; 290(6):234-45. PubMed ID: 3909812
[TBL] [Abstract][Full Text] [Related]
7. Review: Renal osteodystrophy--pathogenesis and treatment.
Cushner HM; Adams ND
Am J Med Sci; 1986 Apr; 291(4):264-75. PubMed ID: 3518448
[TBL] [Abstract][Full Text] [Related]
8. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
[TBL] [Abstract][Full Text] [Related]
9. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
[TBL] [Abstract][Full Text] [Related]
10. Elevated bone aluminum content in dialysis patients without osteomalacia.
McCarthy JT; Kurtz SB; McCall JT
Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380
[TBL] [Abstract][Full Text] [Related]
11. Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient.
Felsenfeld AJ; Gutman RA; Llach F; Harrelson JM; Wells SA
Miner Electrolyte Metab; 1984; 10(3):166-72. PubMed ID: 6727802
[TBL] [Abstract][Full Text] [Related]
12. Effect of calcitonin on hemodialysis patients with hypercalcemia and renal osteodystrophy.
Carney SL; Epstein MT
Uremia Invest; 1984-1985; 8(2):97-101. PubMed ID: 6537690
[TBL] [Abstract][Full Text] [Related]
13. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
Voigts AL; Felsenfeld AJ; Llach F
Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
[TBL] [Abstract][Full Text] [Related]
14. Plasma parathormone, calcium and phosphorus in patients with renal osteodystrophy undergoing chronic hemodialysis.
Genuth SM; Sherwood LM; Vertes V; Leonards JR
J Clin Endocrinol Metab; 1970 Jan; 30(1):138-40. PubMed ID: 5409532
[No Abstract] [Full Text] [Related]
15. Hypercalcemia in patients with advanced chronic renal failure not yet requiring dialysis.
Greenberg A; Piraino BM; Bruns FJ
Am J Nephrol; 1989; 9(3):205-10. PubMed ID: 2757079
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism.
Lumb GA; Stanbury SW
Am J Med; 1974 Jun; 56(6):833-9. PubMed ID: 4831321
[No Abstract] [Full Text] [Related]
17. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
[TBL] [Abstract][Full Text] [Related]
18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
19. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
20. Renal osteodystrophy in CAPD.
Hutchison AJ; Freemont AJ; Lumb GA; Gokal R
Adv Perit Dial; 1991; 7():237-9. PubMed ID: 1680434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
